Clinical trial · Interventional
Lisaftoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia Patients
Lisaftoclax for Prevention of Differentiation Syndrom (DS) in Acute Promyelocytic Leukemia (APL) Patients : An Open-lable, Single-arm, Multicenter, Phase Ⅱ Clinical Trail
NCT07597941CI-TRIAL-00116297not yet recruitingPhase 2 / Phase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is to assess the efficacy and safety of Lisaftoclax for prevention of DS in APL patients undergoing ATRA/ATO induction regimen.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Promyelocytic Leukemia (APL) | Acute Promyelocytic Leukemia | ONTOLOGY_EXACT | 0.85 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Lisaftoclax (APG-2575) | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Lisaftoclax for Prevention of Differentiation Syndrom
- interventionNames
- Drug: Lisaftoclax (APG-2575)
Primary outcomes (1)
- measure
- the rate of Differentiation Syndrom
- timeFrame
- the induction regimen (21 days to 28 days)
- description
- DS, known as retinoic acid syndrome, is a severe complication of ATRA or ATO during the differentiation of promyelocytes. Signs of DS are presented as fever, weight gain, hypertension, dyspnoea, radiographic opacities, peripheral edema and acute renal failure.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 16 Years
Show eligibility criteria text
Inclusion Criteria: * 1\. Patients aged ≥ 16 years old. * 2\. Confirmed diagnosis of acute promyelocytic leukemia (APL) by morphology, flow cytometry, and cytogenetics/molecular testing. * 3\. ECOG performance status 0-2. * 4\. Adequate organ function: * Serum creatinine ≤ 1.5 × ULN * Total bilirubin ≤ 2 × ULN * AST/ALT ≤ 3 × ULN * 5\. Able to understand and sign the informed consent form. Exclusion Criteria: * 1\. Concurrent participation in another interventional clinical trial. * 2\. History of other malignancies within the past 5 years (except cured basal cell carcinoma or in situ cervical cancer). * 3\. Severe uncontrolled infection or other serious underlying diseases that may interfere with study treatment or follow-up. * 4\. Known hypersensitivity to lisaftoclax, ATRA, ATO, or any components of the study regimen. * 5\. Pregnant or breastfeeding women.
References
Publications (0)
Data not yet available
No reference posted for this study.